Song Ruilin: we can't expect imports to meet clinical needs through pharmaceutical innovation

Source: People's Network Health Channel / Wang Yupeng 2016-11-16 the first "China Pharmaceutical Innovation and investment conference" jointly sponsored by China pharmaceutical innovation promotion association and China Securities Association was held in Suzhou Industrial Park from November 14 to 16 Song Ruilin, executive chairman of China pharmaceutical innovation promotion association, said in an exclusive interview with people.com that to promote pharmaceutical innovation from both strategic and tactical aspects, we can't expect drug imports Song Ruilin said that from a strategic point of view, there are still many clinical drug needs in China that have not been met Throughout the world, innovation in every country is closely related to its needs For example, the incidence rate of lung cancer in the United States is very high, so many lung cancer drugs have been developed But the incidence of gastric cancer in the United States is very low, so there are few studies China has a high incidence rate of gastric cancer but few innovative drugs "So, from a strategic point of view, innovation is first and foremost to meet the clinical needs of our country, and we cannot rely on others." Song Ruilin's analysis from the tactical level: imported patent drugs are often expensive, and social tolerance and patient accessibility are affected It can be said that the high price of imported drugs is one of the reasons why it is difficult and expensive for us to see a doctor How to crack it? We should give full play to social forces, be brave in innovation, and reduce costs and meet clinical drug demand through innovation "To sum up, we must solve our own problems, not rely on imports, which is the real security." Song Ruilin said.